Matinas Biopharma Cash Flow - Annual (NYSEMKT:MTNB)

Add to My Stocks
$0.41 $0.01 (2.38%) MTNB stock closing price Sep 19, 2018 (Closing)

For analyzing any company like Matinas Biopharma from an investment perspective, its important to check the cash flow statement. Financials statements like the Matinas Biopharma income statement and Matinas Biopharma balance sheet show that the company has profits and debt, while the cash flow statement provides details of cash flow movments. Matinas Biopharma cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Matinas Biopharma had cash and cash equivalents of $4.1M at the beginning of the year and $7.3M at year end for 2017. MTNB decrease in investments stood at a value of $-0.94M for the latest year 2017.

View details of Matinas Biopharma cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Net Income Cash Flow
-15.48M-7.59M-9.13M-10.22M-3.71M-0.11M-
Depreciation Depletion Amortization Cash-Flow-------
Net Increase (Decrease) in Assets Liabilities--0.09M-0.32M----
Cash From (used in) Discontinued Operations-------
Other Adjustments Net3.39M1.52M1.6M1.97M---
Net Cash from (used by) Operating Activities
-11.45M-6.11M-7.81M-7.96M-2.98M-0.05M-
Increase (Decrease) in Prop Plant And Equipment-0.94M--0.07M-0.28M-0.09M--
Acquisition Disposition of Subsidiaires-------
Increase (Decrease) in Investments-------
Other Cash Inflow (Outflow) from Investment Activities-------
Net Cash from (used by) Investment Activities
-0.94M--0.01M-0.28M-0.09M--
Issuance (Purchase) of Equity Shares15.68M8.31M--15.9M--
Issuance (Repayment) of Debt Securities-0.34M-0.16M-0.05M--0.02M--
Increase (Decrease) in Bank & Other Borrowings-------
Payment of Dividends & Other Cash Distributions-------
Other Cash from (used by) Financing Activities--1.15M8.51M--2.38M-0.04M-
Net Cash from (used by) Financing Activities
15.6M6.99M8.45M-13.49M--
Effect of Exchange Rate Changes on Cash-------
Net Change in Cash & Cash Equivalents
3.2M---8.24M10.41M--
Cash & Equivalents at Beginning of Year4.1M3.22M2.59M10.84M---
Cash & Equivalents at Year End7.3M4.1M3.22M2.59M10.84M--
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Matinas Biopharma stock price history provides insight into historical stock price fluctuations, and Matinas Biopharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Matinas Biopharma has cash of $7.3M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Matinas Biopharma stock price.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-11.45M for MTNB.
  • Cash Flow from investment activities: Matinas Biopharma used $-0.94M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Matinas Biopharma earned $15.6M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Matinas Biopharma Cash Flow